Contracts › 75F40122C00181
75F40122C00181: Calibrating Rwe Studies in Oncology Against Randomized Trials
Awarded to Brigham & Womens Hospital Inc by Food and Drug Administration (FDA).
$3.7Mobligated
$4.7Mpotential value
29 January 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75F40122C00181 |
|---|---|
| Awardee | Brigham & Womens Hospital Inc |
| Awarding agency | Food and Drug Administration (FDA) |
| Awarding office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN11 Health R&D Services; Health Care Services; Basic Research |
| Place of performance | MD |
| Offers received | 1 |
| Period of performance | 21 September 2022 to 29 January 2027 |
| Potential end | 29 January 2027 |
| Estimated recompete solicitation | Now / imminent (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record